Malta - English - Malta Medicines Authority

cipla (eu) limited hillbrow house, hillbrow road, esher, surrey, kt10 9nw, united kingdom - mometasone furoate - nasal spray, suspension - mometasone furoate 50 µg - nasal preparations

Namibia - English - Namibia Medicines Regulatory Council

msd (pty) ltd - mometazone furoate monohydrate - spray - mometazone furoate monohydrate eq. to mometazone furoate 50ng/spray

Malta - English - Malta Medicines Authority

1 a pharma gmbh keltenring 1+3, 82041 oberhaching, germany - mometasone furoate - cream - mometasone furoate 0.1 % (w/w) - corticosteroids, dermatological preparations

Ireland - English - HPRA (Health Products Regulatory Authority)

cipla (eu) limited - mometasone furoate monohydrate - nasal spray suspension - 50 mcg/acutuation - corticosteroids

Ireland - English - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - mometasone furoate monohydrate - nasal spray suspension - 50 mcg/acutuation - corticosteroids

Australia - English - Department of Health (Therapeutic Goods Administration)

ego pharmaceuticals pty ltd - mometasone furoate -

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - mometasone (unii: 8hr4qj6dw8) (mometasone - unii:8hr4qj6dw8) - mometasone 50 ug - mometasone furoate nasal spray 50 mcg is indicated for the treatment of the nasal symptoms of seasonal allergic and perennial allergic rhinitis, in adults and pediatric patients 2 years of age and older. mometasone furoate nasal spray 50 mcg is indicated for the relief of nasal congestion associated with seasonal allergic rhinitis, in adults and pediatric patients 2 years of age and older. mometasone furoate nasal spray 50 mcg is indicated for the prophylaxis of the nasal symptoms of seasonal allergic rhinitis in adult and adolescent patients 12 years and older. mometasone furoate nasal spray 50 mcg is indicated for the treatment of nasal polyps in patients 18 years of age and older. mometasone furoate nasal spray is contraindicated in patients with known hypersensitivity to mometasone furoate or any of its ingredients. teratogenic effects: pregnancy category c: there are no adequate and well-controlled studies in pregnant women. mometasone furoate nasal spray 50 mcg, like other corticosteroids, should be

United States - English - NLM (National Library of Medicine)

warrick pharmaceuticals corporation - mometasone furoate (unii: 04201gdn4r) (mometasone - unii:8hr4qj6dw8) - lotion - 1 mg in 1 ml - mometasone furoate lotion 0.1% (mometasone furoate topical solution usp) is a medium potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. since safety and efficacy of mometasone furoate lotion 0.1% have not been established in pediatric patients below 12 years of age, its use in this age group is not recommended, (see precautions – pediatric use ). mometasone furoate lotion 0.1% (mometasone furoate topical solution usp) is contraindicated in those patients with a history of hypersensitivity to any of the components in the preparation.

United States - English - NLM (National Library of Medicine)

harris pharmaceutical, inc. - mometasone furoate (unii: 04201gdn4r) (mometasone - unii:8hr4qj6dw8) - mometasone furoate 1 mg in 1 ml - mometasone furoate topical solution usp, 0.1% (lotion) is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 12 years of age or older. none. teratogenic effects pregnancy category c: there are no adequate and well-controlled studies in pregnant women. therefore, mometasone furoate topical solution usp, 0.1% (lotion) should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. when administered to pregnant rats, rabbits, and mice, mometasone furoate increased fetal malformations. the doses that produced malformations also decreased fetal growth, as measured by lower fetal weights and/or delayed ossification. mometasone furoate also caused dysto